iSpecimen Inc. Contract Liability (Deferred Revenue)
iSpecimen Inc. (ISPC) had Contract Liability (Deferred Revenue) of $124.70 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-14
- 2026-06-30: Contract with Customer, Liability, Current $124.70K.
- 2026-03-31: Contract with Customer, Liability, Current $189.74K.
- 2025-12-31: Contract with Customer, Liability, Current $192.53K.
- 2025-09-30: Contract with Customer, Liability, Current $155.51K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $124.70K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $189.74K 10-Q · filed 2026-05-18 |
| 2025-12-31 | $192.53K 10-Q · filed 2026-08-14 |
| 2025-09-30 | $155.51K 10-Q · filed 2025-11-17 |
| 2025-06-30 | $164.07K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $270.21K 10-Q · filed 2025-05-19 |
| 2024-12-31 | $360.71K 10-K · filed 2026-04-01 |
| 2023-12-31 | $415.77K 10-K · filed 2025-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |